Keyphrases
Gastric Cancer
56%
Chemotherapy
46%
5-fluorouracil (5-FU)
45%
Phase II Trial
38%
Oxaliplatin
38%
Tumor
36%
Adenocarcinoma of the Esophagogastric Junction
35%
Gastroesophageal Junction Cancer
34%
Locally Advanced
34%
Overall Survival
33%
Cisplatin
32%
Docetaxel
30%
Trastuzumab
29%
Esophagogastric Adenocarcinoma
29%
Ramucirumab
29%
Capecitabine
25%
Leucovorin
24%
Randomized Phase II Trial
24%
Fluorouracil
23%
Gastroesophageal Adenocarcinoma
22%
Fluoropyrimidine
21%
Neoadjuvant Chemotherapy
20%
Metastatic Gastric Cancer
20%
Cetuximab
20%
Programmed Death-ligand 1 (PD-L1)
19%
Preoperative Chemotherapy
18%
Paclitaxel
18%
Gastroesophageal Junction
18%
Advanced Gastric Cancer
18%
Histological Response
17%
Advanced or Metastatic
16%
Neoadjuvant
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Esophageal Cancer
16%
Second-line Treatment
15%
Progression-free Survival
15%
Standard of Care
15%
Nivolumab
15%
Pembrolizumab
14%
Quality of Life
14%
Metastatic Colorectal Cancer (mCRC)
14%
Immune Checkpoint Inhibitors
13%
Perioperative Care
13%
Treatment Options
13%
Treatment Strategy
13%
Stomach Adenocarcinoma
13%
FOLFOX
13%
Elderly Patients
13%
HER2-positive
12%
Phase II Study
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Adenocarcinoma
82%
Abdominal Cancer
73%
Malignant Neoplasm
64%
Neoplasm
49%
Fluorouracil
46%
Overall Survival
37%
Oxaliplatin
34%
Folinic Acid
33%
Cisplatin
31%
Docetaxel
31%
Ramucirumab
28%
Phase II Trials
28%
Trastuzumab
24%
Fluoropyrimidine
23%
Immunotherapy
22%
Diseases
22%
Paclitaxel
18%
Capecitabine
17%
Biological Marker
17%
Cetuximab
15%
Adverse Event
15%
Progression Free Survival
14%
Nivolumab
13%
Pembrolizumab
12%
Epidermal Growth Factor Receptor 2
12%
Taxane
11%
Gamma Urogastrone
11%
Squamous Cell Carcinoma
11%
Epidermal Growth Factor Receptor
10%
Disease Free Survival
10%
Esophageal Squamous Cell Carcinoma
9%
Stomach Adenocarcinoma
9%
Polyethylene Terephthalate
9%
Monotherapy
9%
Survival Rate
8%
Ipilimumab
8%
Placebo
8%
Irinotecan
8%
Clinical Trial
8%
Esophageal Adenocarcinoma
8%
Esophagus Cancer
8%
First-Line Chemotherapy
7%
Esophagus Carcinoma
7%
Metastatic Colorectal Cancer
7%
Chemoradiation Therapy
7%
Chemotherapy Induced Nausea and Vomiting
6%
Remission
6%
Skin Toxicity
6%
Carcinoma
6%
Medicine and Dentistry
Adenocarcinoma
81%
Malignant Neoplasm
67%
Abdominal Cancer
54%
Neoplasm
50%
Gastroesophageal Junction
43%
Immunotherapy
31%
Overall Survival
28%
Oxaliplatin
23%
Diseases
23%
Docetaxel
21%
Arm
20%
Trastuzumab
20%
Fluorouracil
19%
Polyethylene Terephthalate
19%
Folinic Acid
18%
Neoadjuvant Chemotherapy
18%
Biological Marker
17%
Fluoropyrimidine
17%
Cancer
17%
Targeted Therapy
17%
Systemic Therapy
15%
Chemoradiotherapy
15%
Pembrolizumab
15%
Cisplatin
14%
Clinical Trial
13%
Nivolumab
13%
Progression Free Survival
12%
Elderly Patient
12%
Programmed Death-Ligand 1
12%
Ramucirumab
11%
Quality of Life
11%
Esophageal Cancer
11%
Metastatic Carcinoma
11%
FOLFOX
11%
Phase II Trials
10%
Metastatic Colorectal Cancer
10%
Positron Emission Tomography
10%
Disease Free Survival
9%
Carcinoma
9%
Ipilimumab
9%
Stomach Carcinoma
9%
Paclitaxel
8%
Survival Rate
8%
Monotherapy
8%
Esophageal Adenocarcinoma
8%
Preoperative Chemotherapy
7%
Programmed Cell Death
7%
Esophagus
7%
Adverse Event
7%
Stomach Adenocarcinoma
7%